Eliglustat is an oral therapy approved in the European Union (2015) and the United States (2014) as a first-line treatment for adults with type 1 Gaucher disease who have compatible CYP2D6 metabolism phenotypes. This evidence concerns the gene CYP2D6 and Gaucher disease type 1.